Display options
Cite
Huang W, Cao Z, Zeng L, et al. nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T-cell lymphoma, not otherwise specified. Oncol Lett. 2019;18(4):3803-3810doi: 10.3892/ol.2019.10703.
Huang, W., Cao, Z., Zeng, L., Guo, L., Liu, X., Lv, N., & Feng, X. (2019). nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T-cell lymphoma, not otherwise specified. Oncology letters, 18(4), 3803-3810. https://doi.org/10.3892/ol.2019.10703
Huang, Wenting, et al. "nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T-cell lymphoma, not otherwise specified." Oncology letters vol. 18,4 (2019): 3803-3810. doi: https://doi.org/10.3892/ol.2019.10703
Huang W, Cao Z, Zeng L, Guo L, Liu X, Lv N, Feng X. nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T-cell lymphoma, not otherwise specified. Oncol Lett. 2019 Oct;18(4):3803-3810. doi: 10.3892/ol.2019.10703. Epub 2019 Aug 02. PMID: 31516591; PMCID: PMC6733006.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2019 Oct;18(4):3803-3810. doi: 10.3892/ol.2019.10703. Epub 2019 Aug 02.

nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T-cell lymphoma, not otherwise specified.

Oncology letters

Wenting Huang, Zheng Cao, Linshu Zeng, Lei Guo, Xiuyun Liu, Ning Lv, Xiaoli Feng

Affiliations

  1. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, P.R. China.
  2. Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, Guangdong 518116, P.R. China.

PMID: 31516591 PMCID: PMC6733006 DOI: 10.3892/ol.2019.10703

Abstract

Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is an aggressive lymphoma associated with a poor outcome. To date, the factor consistently associated with prognosis is the International Prognostic Index (IPI) score; however, it is considered that the IPI score cannot be beneficial for guiding potential targeted therapies. New scoring systems have recently been developed. The aim of the present study was to observe the expression of NME/NM23 nucleoside diphosphate kinase 1 (nm23), nuclear DNA topoisomerase 2-α (TOP2A), multiple myeloma oncogene-1 (MUM-1) and vascular endothelial growth factor (VEGF), and evaluate their prognostic value in PTCL-NOS. A retrospective analysis of 124 cases of PTCL-NOS showed that 70/122 (57.4%) cases were positive for nm23, 71/122 (58.2%) for TOP2A, 30/119 (25.2%) for MUM-1 and 64/122 (52.5%) for VEGF. Of note, 50/122 cases concurrently expressed nm23, TOP2A and VEGF. The univariate analysis results revealed that the nm23 (P=0.012), TOP2A (P=0.002) and VEGF (P=0.008) expression had a negative prognostic effect in patients with PTCL-NOS, while the MUM-1 expression did not have a significant prognostic value (P=0.918). In addition, the concurrent expression of nm23, TOP2A and VEGF was significantly associated with a worse prognosis (P=0.002). However, in multivariate Cox regression analysis, the concurrent expression of nm23, TOP2A and VEGF tended to predict a worse prognosis, however the P-value was borderline (hazard ratio, 1.495; 95% confidence interval, 0.993-2.250; P=0.054). It is speculated that there may be an association among the expression of nm23, TOP2A and VEGF, and that their expression may serve as a promising prognostic factor for PTCL-NOS.

Keywords: NME/NM23 nucleoside diphosphate kinase 1; immunohistochemistry; not otherwise specified; nuclear DNA topoisomerase 2-α; peripheral T-cell lymphoma; prognosis; vascular endothelial growth factor

References

  1. Blood. 1999 Nov 15;94(10):3541-50 - PubMed
  2. Blood. 2004 Jan 1;103(1):275-82 - PubMed
  3. Br J Haematol. 2003 Nov;123(4):621-30 - PubMed
  4. Blood. 2004 Apr 1;103(7):2474-9 - PubMed
  5. Clin Cancer Res. 2004 Apr 1;10(7):2482-90 - PubMed
  6. J Clin Oncol. 2007 Aug 1;25(22):3321-9 - PubMed
  7. Blood. 2008 Jun 15;111(12):5496-504 - PubMed
  8. J Clin Oncol. 2008 Sep 1;26(25):4124-30 - PubMed
  9. Ann Hematol. 2009 Feb;88(2):111-9 - PubMed
  10. Virchows Arch. 2010 Jun;456(6):671-9 - PubMed
  11. Nature. 2010 May 27;465(7297):483-6 - PubMed
  12. J Oncol. 2010;2010:729725 - PubMed
  13. Curr Hematol Malig Rep. 2010 Oct;5(4):222-8 - PubMed
  14. Blood. 2011 Mar 24;117(12):3402-8 - PubMed
  15. Clin Cancer Res. 2011 May 1;17(9):2893-9 - PubMed
  16. Diagn Pathol. 2011 Aug 22;6:77 - PubMed
  17. J Clin Oncol. 2013 Jun 1;31(16):1970-6 - PubMed
  18. Bosn J Basic Med Sci. 2013 May;13(2):72-7 - PubMed
  19. Am J Surg Pathol. 2013 Aug;37(8):1242-51 - PubMed
  20. Int J Hematol. 2014 Mar;99(3):227-39 - PubMed
  21. Ann Hematol. 2015 Feb;94(2):239-47 - PubMed
  22. Histol Histopathol. 2015 Mar;30(3):345-52 - PubMed
  23. Appl Immunohistochem Mol Morphol. 2016 Mar;24(3):167-78 - PubMed
  24. Dis Markers. 2015;2015:786790 - PubMed
  25. Br J Haematol. 2015 Nov;171(3):366-72 - PubMed
  26. Int J Gynecol Cancer. 2016 Feb;26(2):325-30 - PubMed
  27. Ann Vasc Surg. 2016 Feb;31:111-23 - PubMed
  28. Genet Mol Res. 2015 Dec 02;14(4):15597-608 - PubMed
  29. Br J Haematol. 2017 Mar;176(5):750-758 - PubMed
  30. Urology. 2017 Apr;102:265.e1-265.e7 - PubMed
  31. Curr Probl Cancer. 2017 Jan - Feb;41(1):80-93 - PubMed
  32. Virology. 2017 Jun;506:110-120 - PubMed
  33. J Cancer. 2017 Mar 29;8(6):1018-1024 - PubMed
  34. Br J Dermatol. 2018 Jan;178(1):e11-e12 - PubMed
  35. Dig Dis Sci. 2017 Oct;62(10):2790-2800 - PubMed
  36. Rinsho Ketsueki. 2017;58(8):905-911 - PubMed
  37. Genom Data. 2017 Nov 04;14:132-140 - PubMed
  38. World J Surg Oncol. 2017 Nov 29;15(1):211 - PubMed
  39. Gene. 2018 Mar 20;647:306-311 - PubMed
  40. J Cancer. 2018 Feb 12;9(5):851-860 - PubMed
  41. Br J Haematol. 2018 Jun;181(6):760-769 - PubMed
  42. Head Neck. 2018 Sep;40(9):2020-2028 - PubMed
  43. Eur J Radiol. 2018 Sep;106:160-166 - PubMed
  44. Cancer Res. 1971 Nov;31(11):1860-1 - PubMed
  45. N Engl J Med. 1993 Sep 30;329(14):987-94 - PubMed

Publication Types